For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

By Andrew Silver SHANGHAI, July 14 (Reuters) - Shares in China's Dizal Pharmaceutical rose 20% on Tuesday, after the ...

AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer ...

AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive ...

Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target ...

AstraZeneca and Ionis Pharmaceuticals Inc.’s gene silencer drug Wainua failed to help prevent heart problems in patients with ...

AstraZeneca , a UK drugmaker known for its cancer medicines, faced a rare clinical setback after Wainua, a gene-silencing heart drug it i ...

The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a ...

AstraZeneca (AZN 5.74%) fell over 8% ahead of the opening bell after a late-stage clinical trial for its heart disease drug ...

Finance News; AstraZeneca shares fall 9% as cardiovascular drug Wainua fails test; AstraZeneca shares fall 9% as cardiovascular drug Wainua fails test ...